首页> 美国政府科技报告 >Parametric PET/MR Fusion Imaging to Differentiate Aggressive from Indolent Primary Prostate Cancer with Application for Image-Guided Prostate Cancer Biopsies.
【24h】

Parametric PET/MR Fusion Imaging to Differentiate Aggressive from Indolent Primary Prostate Cancer with Application for Image-Guided Prostate Cancer Biopsies.

机译:参数化pET / mR融合成像以区分侵袭性和惰性前列腺癌与应用于图像引导的前列腺癌活组织检查。

获取原文

摘要

The study investigates whether fusion PET/MRI imaging with 18F-choline PET/CT and diffusion-weighted MRI can be successfully applied to target prostate cancer using image-guided prostate biopsies. The study further aims to establish whether fusion PET/MRI-derived parametric imaging parameters identify significant prostate cancer better than standard prostate biopsies. In order to achieve these objectives, prostate cancer patients will undergo PET and MR imaging, followed by standard prostate biopsy with additional targeted prostate biopsies. Biopsy samples will undergo histological evaluation and target metabolite analysis to evaluate underlying metabolic changes observed with prostate cancer progression. Depending on the pathology result of biopsies, some subjects will undergo prostatectomy involving additional MRI of the prostate specimen and registration of imaging to whole mount pathology. To date, 40 subjects have been enrolled and 32 subjects have completed MRI and PET imaging with subsequent biopsy procedure. An interim analysis has shown that a total of 66 subjects are needed to fully investigate the goals of this research. Accordingly, we have initiated an addendum to the research protocol to extend the recruitment goal to 66 subjects (in 4 years). We are now able to perform targeted prostate biopsies with high precision. The interim analysis from 32 subjects as shown that targeted biopsies increased the number of significant prostate cancer lesions found at biopsy (targeted biopsy: n=12; standard biopsy: n = 5). At the same time, the rate of low grade prostate cancer decreased dramatically (targeted biopsy: n=1; standard biopsy: n = 9). These preliminary data show that targeted biopsies increase the chance to identify significant disease requiring fewer biopsy cores, and decreasing the chance to find (indolent) low grade cancer. The second aim (to assess the value of parametric imaging to identify significant prostate cancer) is currently being evaluated.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号